|
|
Volumn 356, Issue 1416, 2001, Pages 1899-1903
|
|
Clinical effectiveness and cost effectiveness of zanamivir (Relenza): Translating the evidence into clinical practice, a National Institute for Clinical Excellence view
|
|
Author keywords
Appraisal; Clinical; Cost effectiveness; Influenza; National Institute for Clinical Excellence; Zanamivir
|
|
Indexed keywords
INFLUENZA;
ANTIVIRUS AGENT;
GUANIDINE DERIVATIVE;
PYRAN DERIVATIVE;
SIALIC ACID DERIVATIVE;
ZANAMIVIR;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
ECONOMICS;
EVIDENCE BASED MEDICINE;
GOVERNMENT;
HEALTH CARE COST;
HUMAN;
INFLUENZA;
ORGANIZATION;
ORGANIZATION AND MANAGEMENT;
PRACTICE GUIDELINE;
RANDOMIZED CONTROLLED TRIAL;
UNITED KINGDOM;
ANTIVIRAL AGENTS;
EVIDENCE-BASED MEDICINE;
GOVERNMENT AGENCIES;
GREAT BRITAIN;
GUANIDINES;
HEALTH CARE COSTS;
HUMANS;
INFLUENZA, HUMAN;
ORGANIZATIONAL OBJECTIVES;
PYRANS;
RANDOMIZED CONTROLLED TRIALS;
SIALIC ACIDS;
ZANAMIVIR;
|
|
EID: 0035969783
PISSN: 09628436
EISSN: None
Source Type: Journal
DOI: 10.1098/rstb.2001.1003 Document Type: Conference Paper |
|
Times cited : (3)
|
|
References (0)
|
